A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Head and Neck Squamous Cell Carcinoma|Breast Cancer|Sarcoma|Merkel Cell Carcinoma|Cutaneous T-Cell Lymphoma|Melanoma|Renal Cancer|Bladder Cancer|Prostate Cancer|Testicular Cancer|Solid Tumor
Interventions: DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Poly-ICLC
Sponsor: Ludwig Institute for Cancer Research
Collaborators: MedImmune LLC|Cancer Research Institute, New York City